The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 30 April 2004, www.theannals.com, DOI 10.1345/aph.1D166.
 The Annals of Pharmacotherapy: Vol. 38, No. 6, pp. 1060-1064. DOI 10.1345/aph.1D166
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kerst, L. L
Right arrow Articles by Mauro, V. F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kerst, L. L
Right arrow Articles by Mauro, V. F

DRUG INFORMATION ROUNDS

OBJETIVO: Llevar a cabo una revisión acerca de la evidencia de la utilidad de las estatinas en la prevención secundaria de la enfermedad coronariana en pacientes con niveles de colesterol de lipoproteínas de baja densidad (LDL-C por sus siglas en inglés) óptimos o casi óptimos.

FUENTES DE INFORMACIÓN: Se utilizó el sistema de información MEDLINE (1966 a octubre 2003) usando los términos inhibidores de HMG-CoA reductasa, estatinas, enfermedad coronariana, post infarto de miocardio, y colesterol promedio.

SÍNTESIS: Se revisaron estudios de prevención secundaria que utilizaron sujetos con niveles de línea base de LDL-C casi óptimos (<130 mg/dL) u óptimos (<100 mg/dL). Los estudios de prevención secundaria utilizando estatinas que se llevaron a cabo al inicio sugirieron beneficios atenuados. Los estudios más recientes cuestionan estos hallazgos.

CONCLUSIONES: La prevención secundaria de la enfermedad coronariana utilizando las estatinas en aquellos pacientes con LDL-C cercanos a la meta establecida es controversial, aunque la evidencia de los estudios recientes parece ser prometedora.

www.theannals.com


This article has been cited by other articles:


Home page
 CMAJHome page
I. Karp, S.-F. Chen, and L. Pilote
Sex differences in the effectiveness of statins after myocardial infarction
Can. Med. Assoc. J., January 30, 2007; 176(3): 333 - 338.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M. Chello, C. Goffredo, G. Patti, D. Candura, R. Melfi, S. Mastrobuoni, G. Di Sciascio, and E. Covino
Effects of atorvastatin on arterial endothelial function in coronary bypass surgery
Eur. J. Cardiothorac. Surg., December 1, 2005; 28(6): 805 - 810.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kerst, L. L
Right arrow Articles by Mauro, V. F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kerst, L. L
Right arrow Articles by Mauro, V. F

homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.